![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright © 2008 Bartolini et al. Article The formin mDia2 stabilizes microtubules independently of its actin nucleation activity 1Department of Pathology, Anatomy and Cell Biology, Columbia University, New York, NY 10032 2Department of Biology and Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, MA 02454 3Department of Biological Sciences, Lehigh University, Bethlehem, PA 18015 Correspondence to Gregg G. Gundersen: ggg1/at/columbia.edu Received September 5, 2007; Accepted April 3, 2008. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). This article has been cited by other articles in PMC.Abstract A critical microtubule (MT) polarization event in cell migration is the Rho/mDia-dependent stabilization of a subset of MTs oriented toward the direction of migration. Although mDia nucleates actin filaments, it is unclear whether this or a separate activity of mDia underlies MT stabilization. We generated two actin mutants (K853A and I704A) in a constitutively active version of mDia2 containing formin homology domains 1 and 2 (FH1FH2) and found that they still induced stable MTs and bound to the MT TIP proteins EB1 and APC, which have also been implicated in MT stabilization. A dimerization-impaired mutant of mDia2 (W630A) also generated stable MTs in cells. We examined whether FH1FH2mDia2 had direct activity on MTs in vitro and found that it bound directly to MTs, stabilized MTs against cold- and dilution-induced disassembly, and reduced the rates of growth and shortening during MT assembly and disassembly, respectively. These results indicate that mDia2 has a novel MT stabilization activity that is separate from its actin nucleation activity. Introduction Formins are a family of ubiquitous, conserved proteins that are implicated in a wide range of actin-based processes, such as cell polarization, cytokinesis, and cell morphogenesis. Formins are defined by their signature formin homology (FH) 2 domain, which assembles unbranched actin structures from the barbed ends (Pruyne et al., 2002; Sagot et al., 2002). The FH2 domain forms a tethered dimer consisting of two antiparallel elongated actin binding domains (Shimada et al., 2004; Xu et al., 2004). Mutation of conserved tryptophans at the dimerization interface abrogates actin assembly activity, suggesting that the dimer is the functional state of formin proteins (Moseley et al., 2004; Xu et al., 2004). Adjacent to the FH2 domain is a proline-rich FH1 domain that can accelerate the rate of filament elongation through interactions with profilin-bound actin monomers (Sagot et al., 2002; Kovar et al., 2003, 2006; Li and Higgs, 2003; Pring et al., 2003; Moseley et al., 2004; Romero et al., 2004; Vavylonis et al., 2006). Diaphanous-related formins (DRFs) include Dia (diaphanous), DAAM (disheveled-associated activators of morphogenesis), and FRL (formin-related proteins identified in leucocytes) in mammals and Bni1 and Bnr1 in yeast (Higgs and Peterson, 2005; Rivero et al., 2005). The DRF subfamily is characterized by domains that regulate the subcellular localization and formin activation by Rho family GTPases. The binding of Rho-GTP to the GTPase binding domain (GBD) is thought to activate DRFs by relieving an autoinhibitory interaction between the adjacent N-terminal diaphanous inhibitory domain and a short segment located on the C-terminal side of the FH2 domain, the diaphanous autoregulatory domain (DAD; Watanabe et al., 1999; Alberts, 2001; Li and Higgs, 2005; Otomo et al., 2005; Rose et al., 2005). Functional consequences of DRF activation generally depend on the ability of DRFs to nucleate actin polymerization, resulting in the formation of linear actin filaments such as actin cables in yeast or actin fibers and filopodia in higher eukaryotes. Cellular functions mediated by DRFs include both cytoskeletal rearrangements and transcriptional activation of specific promoters such as the serum response element (Copeland and Treisman, 2002). DRF's ability to remodel the actin cytoskeleton has been implicated in cytokinesis, tissue morphogenesis, cell polarity, and cell adhesion, where they appear to be required for filopodia formation, focal adhesion turnover, and, more recently, T cell proliferation and migration (Eisenmann et al., 2007; Goode and Eck, 2007; Gupton et al., 2007; Sakata et al., 2007). Two members of the Dia family in mouse (mDia1 and mDia2) also regulate endocytosis and endosome trafficking, presumably by promoting endosome actin coat formation and dynamics (Tominaga et al., 2000; Gasman et al., 2003; Fernandez-Borja et al., 2005; Wallar et al., 2007). There is growing evidence that formins may also be involved in regulating MT-dependent processes such as meiotic spindle alignment and chromosome congression at mitosis (Leader et al., 2002; Yasuda et al., 2004). Notably, both mDia1 and its interacting protein Pkd2 localize to mitotic spindles (Ishizaki et al., 2001; Kato et al., 2001; Rundle et al., 2004). In Drosophila melanogaster, the formin Cappuccino directly regulates Rho-dependent actin-MT cross talk during ooplasmic streaming and has an MT binding domain (Rosales-Nieves et al., 2006). In migrating fibroblasts, mDia1 stabilizes a subset of MTs downstream of lysophosphatidic acid (LPA)–induced Rho signaling (Palazzo et al., 2001; Wen et al., 2004; Goulimari et al., 2005; Eng et al., 2006). mDia may also contribute to MTOC orientation in fibroblasts and cytotoxic lymphocytes (Yamana et al., 2006; Gomez et al., 2007). The current model for mDia-regulated stabilization of MTs suggests that LPA triggers a Rho/mDia-dependent pathway that also involves EB1, APC, GSK3β, and novel PKCs to generate a polarized array of stabilized MTs oriented toward the leading edge of cells in a wounded monolayer (Palazzo et al., 2001; Wen et al., 2004; Eng et al., 2006). The localization of these stabilized MTs is regulated by integrin signaling (Palazzo et al., 2004), and this is thought to contribute to cell polarity by directing vesicular trafficking and/or actin regulators to the leading edge (Lin et al., 2002). Rho/mDia-stabilized MTs are characterized by elevated levels of posttranslationally detyrosinated α-tubulin, which arises after stabilization through the removal of the C-terminal tyrosine residue (Gundersen et al., 1984, 1987). Detyrosination exposes a glutamate residue at the C terminus of the α-tubulin and, hence, stable MTs that contain elevated detyrosinated α-tubulin are referred to as Glu MTs, as opposed to more dynamic MTs, which contain tyrosinated α-tubulin and are referred to as Tyr MTs (Gundersen et al., 1984, 1987). Analyses of MT plus-end turnover in cells have shown that the stabilization induced by LPA/Rho-mDia signaling is achieved by capping of MT plus ends, which makes them refractory to tubulin subunit exchange (Infante et al., 2000; Palazzo et al., 2001). The biochemical mechanisms of MT stabilization by Rho/mDia proteins are still poorly understood and it is unclear which proteins in the pathway are directly involved in stabilizing this class of MTs. To date, there is no evidence to support a role for formins in directly modulating the dynamics of the MT cytoskeleton, and it remains possible that MT stabilization is a secondary consequence of mDia-mediated assembly and stabilization of actin filaments. In this paper, we show that actin nucleation and MT stabilization by mDia2 are two separate cellular functions of this formin and, further, that the formation of a stable mDia2 dimer is not necessary for MT stabilization. We also demonstrate that purified mDia2 directly stabilizes MTs by inhibiting both polymerization and depolymerization rates and that this activity maps to the FH2 domain. Results I704A and K853A FH1FH2mDia2 mutants are defective in actin assembly in vitro and in vivo Alanine substitutions of Ile 1431 and Lys 1601 completely abolish the actin-nucleating activity of the FH2 domain in the yeast formin Bni1p (Xu et al., 2004) and, at least in the case of the corresponding I704A mutation, in mammalian mDia2 (Harris et al., 2006). These substitutions also eliminate the ability of the FH2 domain to protect barbed ends from heterodimeric capping protein (Xu et al., 2004; Harris et al., 2006). We introduced the analogous mutations (I704A and K853A) in a constitutively active fragment of mDia2 that consists of both the FH1 and 2 domains and lacks the regulatory GBD and DAD domains (Fig. 1 A
We first prepared recombinant His-tagged proteins and tested them for actin assembly using a kinetic assay using pyrene-labeled actin (Fig. 1 B To test whether the actin polymerization defect in vitro correlated with a loss of activity in vivo, we introduced wild-type and mutant forms of FH1FH2mDia2 into serum-starved NIH3T3 cells, which have low levels of assembled actin. We injected the proteins at the minimal concentration at which the wild-type fragment induced actin fibers as assessed by phalloidin staining. Under these conditions both mutants failed to induce actin fibers (Fig. 1, C and D We used total internal reflection fluorescence (TIRF) microscopy to examine the directional movement of mDia2 puncta, which are thought to reflect actin filament growth (Higashida et al., 2004). Consistent with the inability of the mutants to induce actin filaments, we observed fast directional movement of EGFP-FH1FH2mDia2 puncta only with the wild-type construct, as we could not trace linear tracks for most of the EGFP puncta in cells with either of the mDia2 mutants (Fig. 1 E I704A and K853A FH1FH2mDia2 mutants induce stable Glu MTs and bind to APC and EB1 To test whether the actin-deficient FH1FH2mDia2 mutants were able to induce stable Glu MTs, we microinjected them into serum-starved NIH3T3 cells, which contain low levels of stable Glu MTs. Both EGFP-tagged mutants generated stable MTs, although the I704A mutant was reduced ~20% compared with the wild type (Fig. 2, A and B
W630A FH1FH2 mDia2 dimerization mutant induces stable Glu MTs A dimer appears to be the functional state of formin FH2 domains and is required to promote actin nucleation and elongation (Moseley et al., 2004; Shimada et al., 2004; Xu et al., 2004). We questioned whether a functional dimer is also necessary for the stabilization of the MT cytoskeleton and analyzed the dimerization properties of purified wild-type and mutant His-FH1FH2mDia2 proteins by analytical gel filtration (Fig. 3 A
We next tested whether a dimerization mutant, based on the crystal structure of the Bni1p FH2 domain, was capable of inducing stable Glu MTs in cells. We substituted Trp 630 with an Ala, as this residue localizes at the dimerization interface of Bni1 (Xu et al., 2004). Trp 630 is also among the most conserved amino acids in the FH2 domain (Moseley et al., 2004; Xu et al., 2004). Gel filtration analyses of the W630A FH1FH2mDia2 protein showed that it eluted as a major peak at a volume suggesting that it behaves as a monomer rather than a dimer (Fig. 3 B Because dimerization is a necessary requirement for processive actin filament association, we tested the ability of W630A FH1FH2mDia2 to promote F-actin assembly in vitro and in vivo. Pyrene-labeled actin polymerization assays showed that the W630A mutant was >250 times less active than the wild type in nucleating actin (Fig. 3 C When we tested the same construct for induction of stable Glu MTs, we observed that cells expressing W630A EGFP-FH1FH2mDia2 displayed more stable MTs than uninjected neighboring cells, although at a frequency 20% lower than that of cells expressing the wild-type protein (Fig. 3, E and F mDia2 stabilizes MTs against depolymerization in vitro In addition to our data, there is already some evidence suggesting there might be a direct role of mDia on MTs. Previous studies have shown that ΔGBDmDia2 localizes along the length of stabilized MTs (Palazzo et al., 2001). The related protein, mDia1, is also found at a low frequency at the ends of stable MTs in cells (Wen et al., 2004) and has been localized to the mitotic spindle (Kato et al., 2001). However, to date, there have been no studies to explore whether any member of the mDia family shows direct biochemical activity toward MTs. We tested whether mDia2 might exhibit direct MT binding and stabilizing activity and, if so, whether this activity was sufficient to generate capped MTs in vitro, a defining characteristic of Glu MTs in vivo. We first looked at binding of purified recombinant mDia2 to purified MTs or tubulin dimers. We incubated purified His-, GST-, or untagged versions of FH1FH2mDia2 with taxol-assembled MTs or BSA, followed by high-speed centrifugation to separate the MT pellet from soluble unbound material. Both tagged and untagged mDia2 were substantially recovered in the pellet fraction only when MTs were present (Fig. 4 A
We next tested the effect of mDia2 on MT stability and incubated substoichiometric amounts of His- or GST-FH1FH2mDia2 proteins with purified tubulin during spontaneous assembly of MTs at 37°C, followed by a short incubation at 4°C to induce rapid MT depolymerization. SDS gel analyses of MT pellets showed that addition of His- or GST-tagged FH1FH2mDia2 did not increase the level of MTs pelleting at 37°C but did increase the level of MTs pelleting after cold treatment, which is consistent with a role for mDia2 in MT stabilization (Fig. 5 A
Glu MTs in extracted cells are characteristically resistant to disassembly upon dilution (Infante et al., 2000). Thus, we tested whether wild-type and mutant versions of FH1FH2mDia2 fragments could stabilize MTs assembled from purified tubulin against dilution-induced depolymerization. Controls in which MTs were diluted into BSA, heat-denatured mDia2, or His-tagged GSK3β showed low levels of MTs remaining as assayed by immunofluorescence (Fig. 6 A
We next used the MT dilution assay to map the MT-stabilizing activity in FH1FH2mDia2. Recombinant fragments of mDia2 lacking the FH1 and the N terminus of the FH2 (FH2ΔN), portions of the FH2 (FH1FH2ΔC), or both (FH2C) were tested for their ability to protect MTs from dilution-induced depolymerization (Fig. 6, A and B We next tested whether the FH1FH2ΔC and FH2C fragments induced stable MTs in serum-starved cells and found that both induced stable Glu MTs above background levels (Fig. 6, C and D mDia2 decreases tubulin dissociation rates in vitro MT stabilization by the Rho–mDia pathway occurs by inhibition of tubulin loss and gain at MT ends (Palazzo et al., 2001). The stability assays employed in the experiments shown in Figs. 4
Discussion Formins have been extensively characterized for their ability to nucleate and elongate actin filaments (Goode and Eck, 2007). However, their regulation of the MT cytoskeleton, which has been documented both in dividing and migrating cells, is poorly understood. In NIH3T3 cells, mDia1 is both necessary and sufficient to stabilize a subset of MTs (Glu MTs) arranged in the direction of migration downstream from Rho signaling (Palazzo et al., 2001; Goulimari et al., 2005; Eng et al., 2006). mDia also participates in MT stabilization in embryonic endodermal cells and C6 glioma cells (Kodama et al., 2003; Yamana et al., 2006), and evidence exists that mDia associates with MTs and MT ends in vivo (Kato et al., 2001; Palazzo et al., 2001; Wen et al., 2004). However, given the potent and direct effects of mDia on actin assembly, it has remained unclear whether the MT effects might occur as a secondary consequence of mDia-induced actin assembly in cells. In this paper, we show that promotion of actin polymerization and induction of stable Glu MTs by mDia2 can be functionally separated, as two actin polymerization-defective mutants of mDia2 were capable of inducing stable Glu MTs in NIH3T3 cells (Figs. 1 The finding that actin remodeling by mDia2 was not required for stabilizing MTs in cells prompted us to test whether formins could affect MT stability directly. Indeed, we observed that an FH1FH2 fragment of mDia2 stabilized MTs assembled from purified tubulin against depolymerization induced by either cold or tubulin dilution (Figs. 4 Although mDia2's ability to stabilize MTs in vitro is consistent with its activity in generating stable MTs in vivo, the in vitro experiments with axonemes showed that mDia2 did not completely block MTs from growing or shrinking, respectively, as is observed for Rho/mDia-stabilized MTs in vivo. One possibility is that full-length mDia2 has significantly greater activity toward MTs than the FH1FH2 fragment we used in the in vitro experiments. It also seems likely that the capping of MTs observed in vivo requires additional cellular factors that function with mDia. Indeed, APC and EB1, two MT binding proteins themselves, interact with mDia and have been implicated in generating stable MTs induced by LPA (Wen et al., 2004). Also, mDia regulation of GSK3β through novel PKCs has been recently shown to promote MT stabilization in migrating fibroblasts (Eng et al., 2006). It is possible that these factors, and maybe others yet to be discovered, contribute to cap MTs in vivo. This may be accomplished by the formation of a multiprotein complex at MT plus ends in which all the players contribute to the stabilization activity. Because we have localized FH1FH2mDia2 predominantly to the sides of MTs (Fig. 4, E and F We attempted to narrow down the MT stabilization activity on mDia2 but found that there are at least two domains within the FHIFH2 fragment. We could not purify a His-tagged FH1 fragment of mDia2, yet no MT binding was detected for in vitro–translated FH1 fragment (unpublished data). These data suggest that the FH2 fragment contains at least two MT stabilization sites: one encompassing residues 616–910 and the other encompassing residues 910–1040. Each site is sufficient to induce MT stability in vitro and in vivo. The presence of two separate MT binding sites is also consistent with stabilization induced by a dimerization-defective W603A mutant of mDia2 and may explain the apparent bundling of MTs observed in the dilution assays (Figs. 3 Our results show that the MT stabilization domain of mDia2 maps within the same region that is involved in actin polymerization (FH2 core domain). This finding raises the possibility that there is competition between the two cytoskeletal systems for mDia2. Importantly, the activity of mDia2 for actin is in the nanomolar range, whereas that for MTs is in the micromolar range. A simple competition model would predict that if actin and MTs exhibit mutually exclusive for binding to mDia, then redistribution of the formin to the MT cytoskeleton can only occur if the affinity for MTs is significantly increased. Potentially, this may be mediated by any of several regulatory proteins already implicated in stable Glu MT formation downstream of LPA signaling, including the MT TIP proteins APC and EB1 (Wen et al., 2004) and the kinases novel PKC and GSK3β (Eng et al., 2006). Selective activation of these mDia partners could localize mDia to MTs by preferential association of the complexes to MTs or by blocking high-affinity actin binding sites on the formin itself. FH1FH2mDia2 fragments can stabilize MTs directly by inhibiting MT dynamics (Figs. 4 Materials and methods Chemicals All chemicals were obtained from Sigma-Aldrich unless otherwise noted. Cell culture, microinjection, and transfection NIH3T3 cells were grown in DME and 10% calf serum as previously described (Cook et al., 1998; Kreitzer et al., 1999; Palazzo et al., 2001). For microinjection, confluent NIH3T3 cells grown on acid-washed coverslips were serum starved for 48 h in DME plus 10 mM Hepes, pH.7.4, and wounded for 30 min before being microinjected as previously described (Cook et al., 1998; Kreitzer et al., 1999; Palazzo et al., 2001). DNA plasmids in HKCL buffer (10 mM Hepes, pH.7.4, and 140 mM KCL) at 50–200 μg/ml were microinjected into nuclei and allowed to express for 2 h. Purified proteins were microinjected into the cytoplasm in HKCL buffer at 2 mg/ml, unless otherwise indicated, and incubated for 1 h and 30 min before fixation. In the experiments in which His-FH1FH2mDia2 proteins were used, 1 mg/ml of the fusion protein was coinjected with 5 mg/ml of the injection marker human IgG. NIH3T3 cells were transfected in growth medium (DME with 10% calf serum) with Lipofectamine Plus (Invitrogen), according to the manufacturer's specifications, and allowed to express for an additional 18–24 h. Plasmid construction pGST−APC-C (aa 2167−2843) and GST-FH1FH2mDia2 (aa 521–1040) were gifts from R. Baer (Columbia University, New York, NY) and A. Alberts (Van Andel Institute, Grand Rapids, MI), respectively. pGST-EB1 and pHis-FH1FH2mDia2 were constructed as described previously (Wen et al., 2004). pEGFP-FH1FH2mDia2 was prepared by subcloning 521–1040-mDia2 from pEFm-EGFP (Wen et al., 2004) into pEGFP-C1 (Clontech Laboratories, Inc.). K853A, I704A, and W630A mDia2 point mutants were generated on pGST-FH1FH2mDia2 using the QuikChange Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's protocol and using the following synthetic sense oligonucleotide primers: 5′-ttgctcagaacctttcagccttcctgagctccttccg-3′ (I704A); 5′-ctctgtaaactgaaggatacagcatctgcagatcagaaaaccaca-3′ (K853A); and 5′-gaaatcagcatgagaagattgaatgcgttaaagatcggaccaaatgaaat-3′ (W630A). All mutations were subcloned into pEGFP-C1 and pQ30E by cutting the inserts with BamH1 and Xho1 and the vectors with BamH1–Xho1 or BamH1–Sal1, respectively. His-FH1FH2mDia2 deletion constructs were all generated by PCR amplification of pQ30E-FH1FH2mDia2 using KOD HiFi polymerase (EMD) and the following sense oligonucleotide primers: 5′-gcggatccgcagagttacaagctt-3′ (His-FH1FH2ΔC); 5′-gcggatccgctgtcagtactg-3′ (His-FH2ΔN); and 5′-gcggatccgagaagaatttggaa-3′ (His-FH2C). 5′-gcggtaccctgttgaagctgccttc-3′ (His-FH1FH2ΔC) and 5′-gcggtacccactcctgtctcatctc-3′ (His-FH2ΔN and His-FH2C) were chosen as the antisense oligonucleotide primers. pEGFP-FH1FH2ΔC and pEGFP-FH2C were constructed by subcloning the inserts from pQ30E into pEGFP-C1 using BamH1–Kpn1 and Bgl2–Kpn1 to cut inserts and vector, respectively. All constructs were verified by sequencing, and DNA was purified with midiprep kits (QIAGEN). Protein purification and GST pulldown assays GST-tagged proteins (GST-APC-C aa 2167−2843, GST-EB1, and wild-type GST-FH1FH2mDia2) and wild-type and mutant His-FH1FH2mDia2 were expressed in E. coli BL-21 or XL-1 blue cells and affinity purified on agarose-coupled glutathione (GE Healthcare) or nickel resin (Clontech Laboratories, Inc.), respectively, according to the manufacturer's recommended protocols. Untagged FH1FH2mDia2 was obtained by thrombin-mediated cleavage of the GST from the GST fusion protein according to the manufacturer's protocol. Purified proteins were resuspended in HKCL buffer plus 1 mM DTT using Sephadex G-25 PD-10 desalting columns (GE Healthcare). Direct binding was performed by incubating 0.3 μM His-FH1FH2mDia2 with 0.3 μM GST−EB1 or GST−APC-C in modified RIPA buffer (PBS, 1% Nonidet-P40, 1% sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail) for 18 h at 18°C as previously described (Wen et al., 2004). Bound proteins were analyzed by Western blotting with mouse RGS-His antibody (1:10,000). Gel filtration assays Affinity purified His-FH1FH2mDia2 proteins were analyzed by size exclusion chromatography using a Superdex 200 HR 10/30 column (GE Healthcare) and a Controller LCC-501 Plus FPLC system (GE Healthcare). The column was preequilibrated and run in HKCL buffer plus 1 mM DTT. The elution was monitored by absorbance at 280 nm and verified by SDS-PAGE of column fractions followed by Western blotting using mouse RGS-His antibody (1:10,000). The size standards used were ferritin (440 kD), aldolase (158 kD), and BSA (67 kD). Actin assembly kinetics Actin filament assembly assays were performed in 60-μl reactions as previously described (Moseley et al., 2006). In brief, gel-filtered monomeric actin (final concentration 2 μM, 5% pyrene labeled) was converted to Mg-ATP-actin, mixed with the indicated proteins in HKCL buffer or HKCL buffer alone, and then added immediately to 3 μl of 20× initiation mix (40 mM MgCl2, 10 mM ATP, and 1 M KCl). Pyrene fluorescence was monitored at excitation 365 nm and emission 407 nm in a fluorescence spectrophotometer (Photon Technology International) held at the constant temperature of 25°C. The rates of actin assembly were determined from the slopes of the assembly curves at 50% polymerization. Epifluorescence and TIRF microscopy Cells were either fixed in −20°C methanol for 10 min and rehydrated in TBS or fixed in 4% PFA in PBS for 10 min followed by permeabilization with 0.5% Triton X-100 in PBS for 5 min. Glu MTs were detected with a polyclonal rabbit antibody SG that specifically recognizes detyrosinated (Glu) tubulin (Gundersen et al., 1984; 1:400), and tyrosinated (Tyr) MTs were detected with the rat mAb YL1/2 (1:10; European Collection of Animal Cell Cultures). Rhodamine-phalloidin (1:500; Invitrogen) or mouse mAb to actin (C4D6; 1:200) were used to detect the actin cytoskeleton as specified. Secondary antibodies were obtained from Jackson ImmunoResearch Laboratories and were absorbed to minimize cross reaction with other species. Immunostained samples were observed with a microscope (Optiphot; Nikon) using a 60× plan apo objective (1.4 NA) and filter cubes optimized for coumarin, fluorescein/GFP, rhodamine, and Cy5 fluorescence (Nikon). Images were captured with a cooled charge-coupled device camera (MicroMax; KAF 1400 chip; Kodak) using Metamorph software (MDS Analytical Technologies). For live-cell imaging experiments by TIRF microscopy, preparations were observed using a 60× plan apo objective (1.45 NA) on a microscope (TE2000-U; Nikon) equipped with a TIRF illuminator and fiber optic–coupled laser illumination. TIRF illumination was obtained with a separate laser line (Ar ion; 488 nm) using a filter cube optimized for fluorescein/GFP fluorescence (Chroma Technology Corp.). Images were captured with a cooled charge-coupled device camera (Orca ERI; Hamamatsu) using Metamorph software. For live-cell imaging of GFP-fusion mDia2 constructs by TIRF, cells were transfected 24 h before microscopy and images were acquired every 200 ms in GFP recording medium (Ho et al., 1998) plus 1 mM sodium pyruvate and 1% calf serum at 37°C. Kymographs were generated using Metamorph software from image stacks (47 frames) of the selected regions from each transfected cell as indicated. To measure the speed of each particle, a line region was drawn onto the kymograph and width and length logged into Excel (Microsoft). The mean speed was calculated for at least 10 particles. All images for figures were processed with Photoshop (Adobe). MT binding assays PC or DEAE tubulin at 25 μM (purified as described in Mikhailov and Gundersen [1995] and Tian et al. [1997]) was polymerized in PEMG buffer (100 mM Pipes-KOH, pH 6.9, 1 mM EGTA, 2 mM MgCl2, and 1 mM GTP) with 10 μM Taxol at 37°C for 1 h. 12.5 μM of polymerized MTs was incubated with 1 μM of purified mDia2 fragments or BSA for 10 min at 30°C. MT pellets were recovered by centrifugation at 100,000 g for 10 min at 37°C, and matching aliquots of input and MT pellets were loaded onto a 10% SDS-PAGE. Proteins were detected by Coomassie staining. Saturation binding was measured using a range of concentrations of His-FH1FH2mDia2 (0–15 μM) and a fixed amount of MTs (1.5 or 3 μM). MT-bound mDia2 was estimated by Coomassie staining by comparison with a protein standard of known concentration run on the same gel. The fraction of mDia2 sedimenting in the absence of MTs was subtracted from each data point. KD and stoichiometry of binding at theoretical saturation were calculated as best fit values using Prism 4 (GraphPad) assuming one site of binding for mDia2 on the MT polymer. MT shearing was obtained by passing the MTs through a 26G needle at least 10 times and was confirmed by immunofluorescence. Immunostaining analyses of His-FH1FH2mDia2 were performed in flow chambers in which 2 μM of rhodamine-labeled and taxol-stabilized MTs were immobilized onto coverslips precoated with mutant rigor kinesin (E164A; provided by S. Gilbert, University of Pittsburgh, Pittsburgh, PA) in the presence of 1 mM ATP. Non-specific protein binding to glass surfaces was blocked by 1 mg/ml casein before mDia2 perfusion. 2 μM FH1FH2mDia2 in PEM buffer plus additives (10 μM taxol with an oxygen-scavenging cocktail to prevent photodamage, including 220 μg/ml glucose oxidase, 22.5 mM glucose, 36 μg/ml catalase, and 71.5 mM β-mercaptoethanol) or PEM buffer plus additives alone were then perfused in each chamber and incubated with MTs for 5 min. MTs were then washed three times in PEM buffer plus additives, fixed in 1% glutaraldehyde, and processed for immunofluorescence using mouse anti-His and Cy2 anti–mouse for the detection of FH1FH2mDia2. Preparations were observed using a 60× plan apo objective (1.45 NA) on a TE2000-U microscope. Images were captured with a cooled charge-coupled device camera (Orca ERII) using Metamorph software and figures were assembled with Photoshop. MT stability assays PC or DEAE tubulin at 25 μM was induced to polymerize in PEMG buffer with 10% DMSO. Taxol seeds were used in experiments in which the population of surviving MTs was assessed by immunostaining. Polymerization reactions were performed in the presence of 2 μM mDia2 proteins at 37°C for 1 h. To assess MT stability to cold-induced depolymerization, matching aliquots of the samples were centrifuged, as described in the previous section, to isolate the MT pellet. The remaining sample was then incubated at 4°C for 30 min and spun in an ultracentrifuge (TLA100; Beckman Coulter) for 10 min at 60k rpm at 4°C to isolate cold-stable MTs. Samples of the input material, pellets, and supernatants were resolved on 10% SDS-PAGE and the proteins were detected by Coomassie staining. To assess MTs stability to dilution-induced depolymerization, 25 μM DEAE tubulin was polymerized in the presence of taxol seeds to generate longer MTs and recombinant mDia2 fragments at 2 μM were added to MTs diluted 10 times their original volume in PEM buffer (100 mM Pipes-KOH, pH 6.9, 1 mM EGTA, and 2 mM MgCl2) for 10 min at 37°C to induce depolymerization. The reactions were stopped by the addition of 0.5% glutaraldehyde. Matching aliquots of input, diluted, and cold-treated material were then spotted onto poly-lysine–coated coverslips and fixed by incubating with ice-cold methanol for 5 min. MTs were visualized by staining with a rat anti-Tyr tubulin antibody and a secondary Cy3-conjugated anti–rat antibody and epifluorescence microscopy using a microscope (Optiphot) with a 60× plan apo objective (1.4 NA). Images were captured with a cooled charge-coupled device camera (MicroMax) using Metamorph software and figures were assembled using Photoshop. MT bundling before and after dilution was assessed by polymerizing 25 μM MTs using MT seeds in the presence or absence of 2 μM FH1FH2mDia2. MT bundles were sedimented by low-speed centrifugation at 4,500 g for 5 min at room temperature. Matching aliquots of the input materials, pellets, and supernatants were resolved on 10% SDS-PAGE and the proteins were detected by Coomassie staining. MT dynamics analyses MT dynamics analyses were performed with MTs nucleated from sea urchin flagellar axoneme fragments and visualized by video-enhanced DIC microscopy as previously described (Walker et al., 1991; Pryer et al., 1992; Howell et al., 1999). In brief, coverslips were mounted on glass slides using double-stick tape as spacers to create a flow chamber of ~10-μl vol. Sea urchin axonemes were allowed to adhere to the coverslip for 5 min. Chambers were then perfused with 50 μl PEM to remove unbound axonemes and then 5 mg/ml casein to block nonspecific protein binding to glass surfaces. The chamber was then perfused with 50 μl PEM to wash out the casein and finally perfused with a solution of 10 μM tubulin and 1 mM GTP in PEM. In MT assembly reactions to measure MT dynamics, 2 μM His-FH1FH2mDia2 or buffer alone (HKCL + PEM buffer) was added to the MT assembly mixture. The chamber was then warmed on the microscope stage to ~35°C to initiate MT assembly. In most MT disassembly experiments, a single microscope field was viewed for 2–5 min during assembly and then perfused with either buffer (PEM + HKCL) or solutions containing mDia2 (0.5–4 μM in HKCL). MT growth rates during assembly or before perfusion in MT disassembly experiments were used to define plus and minus ends of the axonemes. Mean rates of elongation and shortening for individual MTs were determined by least squares regression analysis of changes in MT length as a function of time. Frequencies of catastrophe were determined by dividing the total number of catastrophes by the sum of the total time spent in elongation for all MTs of one polarity. Taxol-stabilized seeds Taxol-stabilized MT seeds were generated by polymerizing DEAE tubulin at 37°C for 30 min with 100 μM GTP and stepwise addition of Taxol (1–20 μM). MTs were centrifuged at 100,000 g for 10 min at 37°C and resuspended in PEM with 100 μM GTP and 20 μM Taxol. Seeds were generated by passing isolated MTs through a 22-gauge syringe 20 times and then isolated by centrifuging at 100,000 g for 20 min at 4°C. Pellets were washed twice with PEM and resuspended in half of their initial volume in PEM with 100 μM GTP. Online supplemental material Fig. S1 shows that FH1FH2mDia2 stabilizes MTs independently of its tag. Fig. S2 shows that FH1FH2mDia2 bundles MTs in vitro. Fig. S3 shows that FH2C-mDia2 is severely deficient in nucleating actin assembly in vitro. Video 1 shows time lapse of EGFP-FH1FH2mDia2 dynamics in NIH3T3 by TIRF microscopy. Video 2 shows time lapse of W853A EGFP-FH1FH2mDia2 dynamics in NIH3T3 by TIRF microscopy. Video 3 shows time lapse of I704A EGFP-FH1FH2mDia2 dynamics in NIH3T3 by TIRF microscopy. Video 4 shows time lapse of W630A EGFP-FH1FH2mDia2 dynamics in NIH3T3 by TIRF microscopy. Video 5 shows a real-time DIC microscopy video recording of axoneme-nucleated MTs undergoing dilution-induced disassembly in the presence of FH1FH2mDia2. Video 6 shows a real-time DIC microscopy video recording of axoneme-nucleated MTs undergoing dilution-induced disassembly in the presence of HKCL buffer. All movies have been compressed. High-quality uncompressed movies are available upon request. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200709029/DC1. [Supplemental Material Index]
Acknowledgments We thank Erin Vintinner for outstanding technical assistance, Eric Folker for valuable discussions and Biocore analyses, Ying Wen for GST-APC-C and GST-EB1 proteins, Katia Evans and Brett Lauring for help with gel filtration analyses, and members of the Gundersen laboratory for comments on the manuscript. This work was supported by National Institutes of Health Grant (GM 62939 to G.G. Gundersen) and a Telethon-Italy Fellowship (GFP03006 to F. Bartolini). The authors declare that they have no competing financial interests. Notes J.B. Moseley's present address is Laboratory of Yeast Genetics and Cell Biology, The Rockefeller University, New York, NY 10021. Abbreviations used in this paper: DAD, diaphanous autoregulatory domain; DIC, differential interference contrast; DRF, Diaphanous-related formin; FH, formin homology; GBD, GTPase binding domain; LPA, lysophosphatidic acid; MT, microtubule; TIRF, total internal reflection fluorescence. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Science. 2002 Jul 26; 297(5581):612-5.
[Science. 2002]Nat Cell Biol. 2002 Aug; 4(8):626-31.
[Nat Cell Biol. 2002]Mol Cell. 2004 Feb 27; 13(4):511-22.
[Mol Cell. 2004]Cell. 2004 Mar 5; 116(5):711-23.
[Cell. 2004]Mol Biol Cell. 2004 Feb; 15(2):896-907.
[Mol Biol Cell. 2004]Mol Biol Cell. 2005 Jan; 16(1):1-13.
[Mol Biol Cell. 2005]BMC Genomics. 2005 Mar 1; 6(1):28.
[BMC Genomics. 2005]Nat Cell Biol. 1999 Jul; 1(3):136-43.
[Nat Cell Biol. 1999]J Biol Chem. 2001 Jan 26; 276(4):2824-30.
[J Biol Chem. 2001]J Biol Chem. 2005 Feb 25; 280(8):6986-92.
[J Biol Chem. 2005]Nat Cell Biol. 2002 Dec; 4(12):921-8.
[Nat Cell Biol. 2002]Nature. 2004 Apr 15; 428(6984):767-71.
[Nature. 2004]Nat Cell Biol. 2001 Jan; 3(1):8-14.
[Nat Cell Biol. 2001]J Cell Sci. 2001 Feb; 114(Pt 4):775-84.
[J Cell Sci. 2001]J Biol Chem. 2004 Jul 9; 279(28):29728-39.
[J Biol Chem. 2004]Nat Cell Biol. 2001 Aug; 3(8):723-9.
[Nat Cell Biol. 2001]Nat Cell Biol. 2004 Sep; 6(9):820-30.
[Nat Cell Biol. 2004]Mol Biol Cell. 2006 Dec; 17(12):5004-16.
[Mol Biol Cell. 2006]Science. 2004 Feb 6; 303(5659):836-9.
[Science. 2004]Mol Biol Cell. 2002 Jan; 13(1):96-109.
[Mol Biol Cell. 2002]J Cell Sci. 2000 Nov; 113 ( Pt 22)():3907-19.
[J Cell Sci. 2000]Nat Cell Biol. 2001 Aug; 3(8):723-9.
[Nat Cell Biol. 2001]Cell. 2004 Mar 5; 116(5):711-23.
[Cell. 2004]J Biol Chem. 2006 May 19; 281(20):14383-92.
[J Biol Chem. 2006]Nat Cell Biol. 2004 Sep; 6(9):820-30.
[Nat Cell Biol. 2004]J Biol Chem. 2004 Nov 26; 279(48):50250-6.
[J Biol Chem. 2004]Curr Biol. 2003 Aug 5; 13(15):1335-40.
[Curr Biol. 2003]J Biol Chem. 2005 Feb 25; 280(8):6986-92.
[J Biol Chem. 2005]J Biol Chem. 2006 May 19; 281(20):14383-92.
[J Biol Chem. 2006]Science. 2004 Mar 26; 303(5666):2007-10.
[Science. 2004]Mol Biol Cell. 2004 Feb; 15(2):896-907.
[Mol Biol Cell. 2004]Mol Cell. 2004 Feb 27; 13(4):511-22.
[Mol Cell. 2004]Cell. 2004 Mar 5; 116(5):711-23.
[Cell. 2004]Curr Biol. 2003 Aug 5; 13(15):1335-40.
[Curr Biol. 2003]Cell. 2004 Mar 5; 116(5):711-23.
[Cell. 2004]Mol Biol Cell. 2004 Feb; 15(2):896-907.
[Mol Biol Cell. 2004]Nat Cell Biol. 2001 Aug; 3(8):723-9.
[Nat Cell Biol. 2001]Nat Cell Biol. 2004 Sep; 6(9):820-30.
[Nat Cell Biol. 2004]J Cell Sci. 2001 Feb; 114(Pt 4):775-84.
[J Cell Sci. 2001]J Cell Sci. 2000 Nov; 113 ( Pt 22)():3907-19.
[J Cell Sci. 2000]Mol Biol Cell. 2004 Feb; 15(2):896-907.
[Mol Biol Cell. 2004]Cell. 2004 Mar 5; 116(5):711-23.
[Cell. 2004]Nat Cell Biol. 2001 Aug; 3(8):723-9.
[Nat Cell Biol. 2001]Annu Rev Biochem. 2007; 76():593-627.
[Annu Rev Biochem. 2007]Nat Cell Biol. 2001 Aug; 3(8):723-9.
[Nat Cell Biol. 2001]J Biol Chem. 2005 Dec 23; 280(51):42242-51.
[J Biol Chem. 2005]Mol Biol Cell. 2006 Dec; 17(12):5004-16.
[Mol Biol Cell. 2006]Cell. 2003 Oct 31; 115(3):343-54.
[Cell. 2003]J Cell Biol. 1998 Apr 6; 141(1):175-85.
[J Cell Biol. 1998]J Cell Sci. 2000 Nov; 113 ( Pt 22)():3907-19.
[J Cell Sci. 2000]Nat Cell Biol. 2001 Aug; 3(8):723-9.
[Nat Cell Biol. 2001]Mol Biol Cell. 1992 Oct; 3(10):1141-54.
[Mol Biol Cell. 1992]J Cell Sci. 1992 Dec; 103 ( Pt 4)():965-76.
[J Cell Sci. 1992]Nat Cell Biol. 2004 Sep; 6(9):820-30.
[Nat Cell Biol. 2004]Mol Biol Cell. 2006 Dec; 17(12):5004-16.
[Mol Biol Cell. 2006]Nat Cell Biol. 2006 Apr; 8(4):367-76.
[Nat Cell Biol. 2006]Nat Cell Biol. 2004 Sep; 6(9):820-30.
[Nat Cell Biol. 2004]Mol Biol Cell. 2006 Dec; 17(12):5004-16.
[Mol Biol Cell. 2006]J Cell Biol. 1998 Apr 6; 141(1):175-85.
[J Cell Biol. 1998]Mol Biol Cell. 1999 Apr; 10(4):1105-18.
[Mol Biol Cell. 1999]Nat Cell Biol. 2001 Aug; 3(8):723-9.
[Nat Cell Biol. 2001]Nat Cell Biol. 2004 Sep; 6(9):820-30.
[Nat Cell Biol. 2004]Nat Cell Biol. 2004 Sep; 6(9):820-30.
[Nat Cell Biol. 2004]Methods Enzymol. 2006; 406():215-34.
[Methods Enzymol. 2006]Cell. 1984 Oct; 38(3):779-89.
[Cell. 1984]J Cell Sci. 1998 Jul; 111 ( Pt 13)():1767-78.
[J Cell Sci. 1998]Cell Motil Cytoskeleton. 1995; 32(3):173-86.
[Cell Motil Cytoskeleton. 1995]J Cell Biol. 1997 Aug 25; 138(4):821-32.
[J Cell Biol. 1997]J Cell Biol. 1991 Jul; 114(1):73-81.
[J Cell Biol. 1991]J Cell Sci. 1992 Dec; 103 ( Pt 4)():965-76.
[J Cell Sci. 1992]Mol Biol Cell. 1999 Jan; 10(1):105-18.
[Mol Biol Cell. 1999]